Member Info for crumbs

Continuum hopes to become a biotech with its own patented IP exactly how that will transpire will be interesting to watch ... And will it involve moditope?.... could that be Zakari? who knows lol.... what I think it suggests is Lindy is getting very interesting results with using those Cancer Survivor samples and I would speculate that involves moditope...

Not seen one but really it was not an investor presentation it was all about the science going on at the UON biodiscovery institute... and quite a lot is! Scancell being a part of the whole.... our little presentation was a quick overview of the pipeline and that was it....

And continuum are advertising too....

'Continuum Life Sciences is looking for an Alliance Manager to manage our collaborations with university labs. This role has a specific focus on building relationships with research groups and academia to support out work, which aims to bring entirely new types of cancer treatments to patients.

We're looking for someone who is passionate about making a contribution towards the way in which we treat cancer. Continuum is working with a world-class team of experts in immune oncology to research immune mechanisms in long-term cancer survivors. This opportunity will give you first-hand insights into IP and business development strategy, working closely with the decision-making team and interacting with many different scientists in both academia and industry.

https://www.linkedin.com/jobs/continuum-life-sciences-jobs-worldwide?f_C=36166979&trk=top-card_top-card-primary-button-top-card-primary-cta&position=1&pageNum=0

You have to expect the asset sells to contribute towards more BOD wage hikes too... possibly paid in multiple different currencies

Yeah missed it now... no Lindy didn't present it was Vicky Brentville a team science long-termer.... was only a very quick overview so you missed nothing really but a great event with so much science going on at the new unit

Bri chats to them all the time lol

No great reveals and Vicky who presented was nervy but good to see the scancell team science long-termer in action ...

On the livestream
https://www.nottingham.ac.uk/research/research-areas/biodiscovery-institute/outreach-and-public-engagement/launch-event/biodiscovery-institute-launch-event.aspx

It will need one hell of a pr campaign and guess it began to not the greatest start today with a to me visibly uncomfortable BOD...asking shareholders to be patient lol what hold whilst our mates sell ... yeah right!... you cannot win against insiders so why bother playing

' insiders are selling on every good news drifting the sp down while naive investors are buying in not knowing whats happening behind the their back.'
It certainly would explain the recent sp action here....
And no point being on a leaky ship when you're below decks.....the sentiment here is sank

There has to be a bottom somewhere and it would be nice if the constant sellers are all sold out but I reckon many are wary here now.... sure there is a short term 10% bounce to be had but doubtful many will risk holding long... not sure who all the big investors are that Bri talks to daily lol

The last well was a success the sp went up by a tiny few percent on the day and then down again as that is the pattern here it may be the next well success is different but it may keep to the pattern too

Worth remembering Scancell a while ago put together a Clinical Advisory board for modidtope...

'Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces that it has appointed six world-leading clinicians to establish its Clinical Advisory Board ("CAB"). The Board will be chaired by Professor Robert Coleman and will provide strategic guidance and support as the Company prepares for its lead Moditope® candidate, Modi-1, to enter the clinic in Q1 2020 in multiple tumour types, including head and neck, breast and ovarian cancer.



The CAB comprises: Professor Robert Coleman, Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield; Professor Christian Ottensmeier, Professor of Experimental Cancer Medicine at the University of Southampton; Professor Poulam Patel, Professor of Clinical Oncology at the University of Nottingham and Honorary Consultant Medical Oncologist at the Nottingham University Hospitals NHS Trust; Professor Iain McNeish, Professor of Oncology and Head of the Division of Cancer within the Department of Surgery and Cancer, Imperial College London; Professor David Miles, Lead Clinician for breast cancer at Mount Vernon Cancer Centre; and Professor Stephen Chan, Director of Clinical Trials in Breast Cancer and Gynaecological Cancer at Nottingham University Hospital.'

As ever here the market says nah it is not buying it.....

I wouldn't worry about main news and modi1 as if it dissolves tumours in days of a therapeutic dose it is sure to make global headlines and it will not be just another 'potential cure' story it would also be fast tracked and IMHO would not then take 5 years to commercialisation ....

The investment to take moditope from concept to clinic to commercial in as many targets as possible .... as in most cancers would indeed be huge no doubts Merck have spent billions on getting Keytruda through trial ph3's and approved in more and more targets....I know this I also know Merck are a massive company with thousands of employees and resources and capabilities....

more it is about you boil it all down and it is the IP..... some scientists came up with Keytruda many years ago it is now Mercks most valuable asset from It nearly being written off.... and the scientists will not be seeing the full financial rewards of their tech success.....

here that is different Lindy would get her rewards and I think she knows what those could be....I agree is nana... though I haven't to my mind undervalued the potential I did say 50p a quid a fiver even fifty quids... if moditope works especially 'mouse' then it means scancell have an IP that could fill a pharma........ not that we then get a pharm mcap but it puts scancell in a very interesting position considering the scancell patents around 'sIPTM' its like imagining a company 20 years ago owning the patents around check point inhibition.... and that company got to prove that up before ever having to do deal or selling out....

Ivy the perspective is this :

Keytruda that makes up more than a quarter of Mercks revenue
' It was discovered accidentally, by biotech scientists looking for drugs that would tamp down the immune response in patients with autoimmune disease, and would stimulate, not block, PD1. Even after a potent PD1 inhibitor was identified and recognized as a potential cancer drug, the research program had to fight for funding through two mergers and acquisitions. After the program finally wound up at Merck, in 2009, it was considered such a low priority that it was shut down and placed on the out-license list. A term sheet (valuing the program at next to nothing) was reportedly in place, but pulled at the last minute, as promising results from competitor Bristol-Myers Squibb (BMS) motivated a reconsideration of the mechaninism'

'
Pembrolizumab was invented by scientists Gregory Carven, Hans van Eenennaam and John Dulos at Organon after which they worked with Medical Research Council Technology (which became LifeArc) starting in 2006, to humanize the antibody; Schering-Plough acquired Organon in 2007, and Merck & Co. acquired Schering-Plough two years later.[32] Carven, van Eenennaam and Dulos were recognized as Inventors of the Year by the Intellectual Property Owners Education Foundation in 2016.'

I know scancell are not going to be rivalling Merck any time soon lol... what I'm saying is modi1 has the potential to be infact to be much more of a valuable therapeutic than Keytruda and that could become clearer by end of next year and that it is just one product of scancell patented platform.... the rest you just work out yourself ... scancell will need a Merck type company to ever commercialise it ..... what I say is if the trial results are mouse like or even Keytruda like which is what 20% success?...... companies like Merck will want it....... deal/s will be done.... but then there is the rest of the platform :)

I know from past email correspondence with CH that he was also working on trying to nail a modi1 deal.... so who knows...
I have always liked the idea from a risk perspective of going into trial on products with partners as it does offer some protection to investors plus of course, gives a reward pre-data and with a pharma partner already on board you would not have the SCIB1 situation where we never got rewarded for a successful ph1/2

However, it really looks like Lindy wants as much control over her IP for as far as possible as in she is willing to take the risk on because she is confident in the outcome.....

redmile funding means we get to find out .... at least with 3 well 4 products in trials if you throw in Avidimab and the fact modi1 is a 4 in 1 trial means there are plenty of bites so that at least gives investors a better risk/reward profile....

Which all stems from their IP ...... Merck did not invent Keytruda .... no one is going to get moditope cheap if indeed at all they would have to accept a partnering deal and probably not on the whole platform and for sure if it does what it could there would be a large queue to do such a deal... I get the feeling Lindy has a real idea about the worth of her techs and is willing to risk going into trial with no IP dilution... data then deal.... even the MaBs which she is willing to deal on she is not looking to do a low ball deal she'll get that extra data on them.

My main point is this .... if and as of yet we do not know but if scancell has the IP of a pharma that could rival the likes of Merck then don't worry about will it be 50p or a fiver or indeed 50 quids a share never mind the hated 8 quids lol as there is a possibility by the end of next year we will know does Covidity have what it takes to be a leading next-gen Covid vax and does Avidimab prove its worth and is modi1 dissolving late-stage tumours in multiple cancer targets.... and if that is the case then I say scancell will have an IP that could fill a pharma.

The story of Keytruda/Opdivo indeed of mRNA is of scientists who invented them having to give up most of their eventual value in deal/s to pharma to actually get them through trials and to commercialisation...... Lindy has given nothing away this is a unique position.... redmiles funding means Lindy an inventor of potential platforms that could eclipse Checkpoint inhibition and put DNA vaxs above mRNA ones gets the chance to prove that up without needing to sell her babies on the cheap....